PDCD1 and lymphoma: This upregulated NLRP3 inflammasome activation in lymphoma cells can act to modify the antitumor properties of the TME immune cells since it was shown to lead to PD-L1 upregulation in lymphoma cells and, therefore, impaired antitumor cytotoxic T-cell immunity, while it might also lead to an increased proportion of PD-1/TIM-3-expressing T-cells, MDSCs, TAMs, and regulatory T cells, overall favoring lymphoma progression [86].